Spanish Health Ministry to Fund Generic Version of "Champix"

Regulations by 2FIRSTS.ai

May.30.2024

Spanish Health Ministry to Fund Generic Version of "Champix"

Spain's Health Ministry to fund generic version of "Champix" from June, after original version pulled due to impurities.

According to El Mundo on May 29th, the Spanish Ministry of Health will start funding generic versions of "Champix" from June, a drug that was previously removed from the market due to impurities found in the production process of its main component, Varenicline.

Susana Verdejo, director of the Tobacco Prevention and Control Department at the Spanish Ministry of Health, revealed during a World No Tobacco Day meeting on Wednesday (May 29) that the active ingredient varenicline in the pharmaceutical giant Pfizer's drug "Champix" was ordered to be removed from shelves in 2021 by the Spanish Agency of Medicines and Medical Devices (AEMPS) due to the presence of carcinogenic nitrosamine impurities above permitted levels during the manufacturing process. It is expected that in June, the version of the drug produced by the designated manufacturer Normon will be available for sale in Spanish pharmacies.

In Spain, two smoking cessation medications, "Todacitán" and "Recigarum," have received funding. Therefore, there are currently three smoking cessation medications available in Spain.

References:

[1] Sanidad financiará vareniclina, el genérico de 'Champix', como tratamiento para dejar de fumar a partir de junio

Also Read:

[1] British Tourists Face £1,700 Fine for E-Cigarettes in Spain

[2] Spanish Tobacco Prevention Committee Urges Generic Packaging for Tobacco Products

[3] Spanish National Smoking Prevention Plan to be Implemented by Year End

[4] Spain Approves New Smoking Ban Plan with Increased Taxes

[5] Canary Islands Considering Comprehensive Smoking Ban Legislation for Public Health

[6] UK Approves Sale of Promising Smoking Cessation Medication, Cytisine

#Europe #Traditional tobacco #Spain #Regulation

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

British American Tobacco’s Irish unit says VELO pouch sales hit 29m, net revenue climbs to €33.75m

British American Tobacco’s Irish subsidiary PJ Carroll & Co Ltd reported that sales of its Velo nicotine pouches nearly quintupled in 2024 to 29 million units, driving an 11% year-on-year increase in net revenue to €33.75 million. However, amid a heavy tax burden and declining traditional cigarette volumes, the company’s pre-tax profit fell 8% to €5.69 million.

Dec.01 by 2FIRSTS.ai

South Korea’s President Raises Safety Concerns Over Nicotine Alternatives at Cabinet Meeting

South Korea’s Cabinet has approved an amendment to the Tobacco Business Act that legally classifies liquid e-cigarettes as tobacco products. Under the revision, any product containing tobacco or nicotine will fall under tobacco regulation, explicitly including synthetic nicotine vapes. The move addresses long-standing regulatory and taxation gaps.

Dec.16 by 2FIRSTS.ai

Juul Wins UK Court Injunction, Ending Five-Year Legal Battle Against Chinese Vape Infringers

The UK High Court has granted U.S. e-cigarette manufacturer Juul Labs a permanent injunction against four Chinese companies, bringing an end to a five-year patent and trademark infringement case. The defendants — Greensun Technology, Ouch, Gaish, and Airsmo Tech — failed to respond to any court communications or legal filings.

Oct.30 by 2FIRSTS.ai

Malaysia’s Home Ministry Urges Study of IQOS Tobacco Device Ahead of Potential Legislation

Malaysia’s Home Ministry has recommended that the National Poison Centre conduct a study on the IQOS heated tobacco device, developed by a leading global tobacco company. Minister Datuk Seri Saifuddin Nasution Ismail said the research would help the government prepare future legislation addressing emerging nicotine technologies. While health risks remain uncertain, officials stress the need for proactive, adaptable legal frameworks.